Curated News
By: NewsRamp Editorial Staff
June 01, 2026
Nightfood's LIM-E Robot Marks Entry into Pharma Automation
TLDR
- Nightfood Holdings expands into pharma automation with LIM-E robot, opening new high-growth markets beyond hospitality.
- TechForce Robotics deployed LIM-E, an autonomous lab robot, achieving Phase 1 goals under its joint development agreement with Oncotelic.
- AI-enhanced robots like LIM-E improve lab efficiency, freeing scientists to focus on life-saving cancer research and treatments.
- Nightfood's subsidiary TechForce successfully deployed LIM-E, a robot designed for autonomous lab support in pharmaceutical environments.
Impact - Why it Matters
This news matters because it signals a significant expansion of robotics into the pharmaceutical and life sciences sectors, which could drastically improve efficiency, accuracy, and safety in laboratory environments. For investors, the successful deployment of LIM-E validates TechForce Robotics' platform versatility and opens new revenue streams beyond hospitality. For the healthcare industry, automation like LIM-E can accelerate drug discovery and reduce human error, potentially leading to faster development of treatments. The collaboration between Nightfood and Oncotelic highlights the growing trend of cross-industry partnerships to drive innovation in automation, impacting how research labs operate and how pharmaceutical companies approach workflow optimization.
Summary
Nightfood Holdings (OTCQB: NGTF) has announced a significant milestone for its subsidiary, TechForce Robotics, which successfully completed Phase 1 objectives under a joint development agreement with Oncotelic Therapeutics (OTCQB: OTLC). The highlight is the initial deployment of LIM-E, an autonomous laboratory support robot, marking TechForce's first expansion into pharmaceutical and laboratory automation. This deployment validates the adaptability of TechForce's AI-enhanced robotics platform beyond hospitality and service-industry applications into life sciences and pharmaceutical environments. The collaboration, initiated in April 2026, aims to leverage operational data and workflow insights to support future automation initiatives. Both companies plan to continue exploring opportunities in laboratory logistics, manufacturing support, AI-enhanced workflows, and other automation applications. Nightfood views healthcare, life sciences, and pharmaceutical manufacturing as significant long-term growth markets for its Robotics-as-a-Service (RaaS) platform.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. Nightfood Holdings, through its TechForce Robotics platform, develops and deploys autonomous robotic systems to improve operational efficiency, workflow consistency, and scalability across various industries. TechForce Robotics operates via a vertically integrated platform combining proprietary robotics technology, real-world operating environments, and scalable manufacturing, delivering solutions through a RaaS model. The successful Phase 1 completion demonstrates the potential for robotics to transform laboratory workflows, enhancing precision and reproducibility in pharmaceutical research.
For more details, the full press release is available at https://ibn.fm/RFkfL. Investors can find the latest news and updates on NGTF in the company’s newsroom at http://ibn.fm/NGTF. TechMediaWire, a specialized communications platform, has covered this announcement as part of its focus on pioneering technology companies. TechMediaWire is one of over 75 brands within the Dynamic Brand Portfolio @ IBN, delivering access to vast networks and corporate communications solutions.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Nightfood's LIM-E Robot Marks Entry into Pharma Automation
